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Is Lactobacillus reuteri more effective than placebo in reducing crying 
time in breastfed infants with colic?
INTRODUCTION
• Infantile colic (IC) is more than 3 hours of crying per day, over 3 days 
per week, for over 3 weeks, in an otherwise healthy, well-fed infant1
• Affects as many as 1 in 4 newborns2
• Begins in the first 2 weeks of life and usually goes away without 
intervention by 3 or 4 months of age
• Has significant impacts on the infant, the parents, and clinicians3,4
• Studies have found colic to be associated with maternal depression, 
shaken baby syndrome, and early cessation of breastfeeding5
• Gut microbiota of infants with colic have less bacterial diversity and 
lower concentrations of protective, anti-inflammatory bacteria, such 
as lactobacilli6
• Studies have revealed correlation of intestinal dysbiosis with IC2,7
• Evidence suggests that Lactobacillus reuteri may lead to the 
resolution of IC • L. reuteri is significantly more effective than placebo in reducing 
crying-time in infants with colic
• No adverse effects were seen in those receiving L. reuteri
• The findings can only truly be applied to breastfed infants 
• Future studies need to address formula-fed infants
• Future studies should improve sample size, and find ways to verify 
daily diary tracking and product administration
• There is some suggestion L. reuteri given prophylactically could 
prevent the development of colic,11,12 but more studies are needed 
in this area in order to draw any conclusions
• Based on the findings of this analysis, breastfed infants with 
established colic should be treated with L. reuteri supplementation
1. Donna M, Roberts MD, Ostapchuk M, M.D., et al. Infantile colic. Am Fam Physician. 2004;70(4):735-40.
2. Dubois N, Gregory K. Characterizing the intestinal microbiome in infantile colic: Findings based on an integrative review of the literature. 
Biological Research For Nursing. 2016;18(3), 307-15.
3. Turner T, MD, MPH, Palamountain M, MD. Infantile colic: Clinical features and diagnosis. In: UpToDate Feldman M, Grover S (Ed). Up 
To Date. Waltham, MA: 2019. https://www.uptodate.com/contents/infantile-colic-clinical-features-and-diagnosis. Accessed on October 1, 
2019.
4. Camilleri M, Park SY, Scarpato E, Staiano A. Exploring hypotheses and rationale for causes of infantile colic. Neurogastroenterol Motil. 
2017;29(2):10.1111/nmo.12943. doi:10.1111/nmo.12943
5. Sung V, D’Amico F, Cabana MD, et al. Lactobacillus reuteri to treat infant colic: A meta-analysis. Pediatrics. 2018;141(1):e20171811
6. Weerth C, PhD, Fuentes S, PhD, Puylaert P, MSc, et al. Intestinal microbiota of infants with colic: Development and specific signatures. 
Pediatrics. 2012;131(2): 550-58.
7. Tintore M, Colome G, Santas J, et al. Gut microbiota dysbiosis and role of probiotics in infant colic. Arch Clin Microbiol. 2017; 8(4):56. 
doi:10.4172/1989-8436.100056
8. Chau K, Lau E, Greenberg S, et al. Probiotics for infantile colic: A randomized, double-blind, placebo-controlled trial investigating
Lactobacillus reuteri DSM 17938. Journal of Pediatrics. 2015; 166(1): 74-78.
9. Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: A randomized, double-blind, placebo-controlled 
trial. Pediatrics. 2010; 126(3):e526-33.
10. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: A 
randomized, double-blind, placebo-controlled trial. The Journal of Pediatrics. 2013; 162(2):257-62.
11. Indrino F, Di Mauro A, Riezzo G, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: 
A randomized clinical trial. JAMA Pediatr. 2014; 168(3):228-33.
12. Savino F, Ceratto S, Poggi E, et al. Preventive effects of oral probiotic on infantile colic: A prospective, randomised, blinded, controlled 
trial using Lactobacillus reuteri DSM 17938. Bene Microbes. 2015; 6(3):245-51.
ACKNOWLEDGEMENTS
We would like to thank Dr. Massey and Carolyn Schubert 










DSM 17938 for 
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To test the efficacy of 
Lactobacillus reuteri 
in treating infantile 
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its relationship to gut 
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Period Day 7, 14, 21 Day 7, 14, 21 Day 7, 14, 21, 28
Conclusion
Infants in L. reuteri 
group experienced 
more reduction in 
crying time compared 
to placebo
L. reuteri improves 
symptoms of infantile 
colic in breastfed 
infants with colic
L. reuteri reduces 




NNT – Day 
7, 14, 21, 28 8, 3, 2, N/A 2, 3, 4, N/A 7, 2, 2, 3
Figure 1: PRISMA Flow Diagram
Figure 2: Average Crying Time from Baseline to Day 21
